Assessment Of Treatment Regimes And Their Specific Adverse Drug Reactions In Colorectal Cancer Patients Receiving Chemotherapy

Abstract

Background: Colorectal cancer treatment often involves chemotherapy regimens like FOLFOX and FOLFIRI. While effective, these regimens can cause adverse drug reactions that impact patient quality of life. This study aims to assess the specific adverse effects of various chemotherapy regimens in CRC patients to enhance treatment safety and efficacy.

Objective: To determine the treatment approaches in various age groups and to assess the suspected adverse drug reactions (ADRs) associated with various medication regimens employed.

Methods: A total of 86 patient records were collected and analysed in our retro-prospective observational study.

Result: The preferred chemotherapy regimen was CAPOX (47.67%), followed by FOLFOX (24.42%). Adverse drug reactions were notable, particularly in FOLFOX (90.47%) and CAPOX with leucovorin (92.85%).

Conclusion: CAPOX was the most commonly prescribed regimen, with significant adverse reactions reported, especially nausea, vomiting, and abdominal pain. FOLFOX and CAPOX with leucovorin also showed high rates of ADRs. Overall, treatment-related adverse effects were prevalent, emphasizing the need for careful management and monitoring of chemotherapy in CRC patients.